Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer

BACKGROUND: Programmed cell death protein 1 (PD‐1) blockade plus radiotherapy may be a promising strategy to improve the prognosis of patients with metastatic non‐small cell lung cancer (NSCLC). However, the optimum combined scheme, treatment time of radiotherapy, and irradiated lesion have not been...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zi‐Chao, Chen, Kai‐Yan, Li, Na, Xie, Ming‐Ying, Sheng, Jia‐Min, Fan, Yun, Huang, Zhi‐Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376180/
https://www.ncbi.nlm.nih.gov/pubmed/35762488
http://dx.doi.org/10.1111/1759-7714.14553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376180/
https://www.ncbi.nlm.nih.gov/pubmed/35762488
http://dx.doi.org/10.1111/1759-7714.14553

Ejemplares similares